IMPACT [gngm]
pioglitazone [orch, phsu]
glycemia [carb]
Atherogenesis [patf]
Dyslipidaemia [dsyn]
Patients [podg]
Diabetes Mellitus, Type 2 [dsyn]
Evaluate [ftcn]
glycemia [carb]
Lipid [lipd]
effects [qlco]
Safety [hcpp]
pioglitazone [orch, phsu]
Patients [podg]
Diabetes Mellitus, Type 2 [dsyn]
Design [acty]
Methods [inpr]
Patients [podg]
N NOS [aapp, imft]
Diabetes Mellitus, Type 2 [dsyn]
Haemoglobin A1c [aapp, bacs]
HbA [aapp, bacs]
Equal [qlco]
Plasma glucose [lbpr]
Fasting [fndg]
Plasma glucose [lbpr]
mmol/dL [qnco]
mg% [qnco]
C-Peptide [aapp, bacs]
nmol/mL [qnco]
Multi [qnco]
Center [spco]
Sites [spco]
DOUBLE BLIND [resa]
Clinical Trial [resa]
randomized [resa]
Receive [qlco]
placebo [topp]
pioglitazone 30 MG [clnd]
pioglitazone [orch, phsu]
Administered [ftcn]
Daily [tmco]
Patients [podg]
Required [ftcn]
Discontinue [fndg]
diabetic [fndg]
Medications [phsu]
weeks [tmco]
Receive [qlco]
Study [mnob]
treatment [ftcn]
Efficacy [qlco]
Parameters [fndg]
included [ftcn]
HbA [aapp, bacs]
Fasting [fndg]
Plasma glucose [lbpr]
C-Peptide [aapp, bacs]
Insulin [aapp, horm, phsu]
Triglycerides [bacs, lipd]
Cholesterol [bacs, strd]
Total Cholesterol [lbpr]
High Density Lipoprotein Cholesterol [bacs, lipd]
Low Density Lipoprotein Cholesterol [bacs, strd]
Adverse event [fndg]
Chemistry [ocdi]
Physical Examinations [hlca]
Record [inpr]
Compared [acty]
placebo [topp]
pioglitazone [orch, phsu]
P NOS [aapp, imft]
Reduced [qlco]
HbA [aapp, bacs]
Point [qnco]
Fasting [fndg]
Plasma glucose [lbpr]
3 5 [qnco]
mmol/L [qnco]
mg dl [qnco]
Fasting [fndg]
C-Peptide [aapp, bacs]
nmol/L [qnco]
Fasting [fndg]
Insulin [aapp, horm, phsu]
pmol/L [qnco]
pioglitazone [orch, phsu]
P NOS [aapp, imft]
Decreased [qnco]
Insulin Resistance [patf]
IR [geoa]
Plus [qlco]
Improved [qlco]
Beta cell [cell]
function [phsf]
Homeostasis model assessment [lbpr]
Compared [acty]
placebo [topp]
Fasting [fndg]
serum triglycerides [lbpr]
Concentrations [menp]
Decreased [qnco]
P NOS [aapp, imft]
High Density Lipoprotein Cholesterol [bacs, lipd]
Concentrations [menp]
Increased [qnco]
P NOS [aapp, imft]
pioglitazone [orch, phsu]
Total Cholesterol [lbpr]
placebo [topp]
Adverse event [fndg]
Profile [lbpr]
pioglitazone [orch, phsu]
placebo [topp]
Drug-induced [ftcn]
elevations [spco]
serum concentration [qnco]
Alanine Transaminase [aapp, enzy]
Hepatotoxicity [inpo]
Conclusions [idcn]
pioglitazone [orch, phsu]
Improved [qlco]
Insulin Resistance [patf]
glycemia [carb]
Triglycerides [bacs, lipd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Suggest [idcn]
pioglitazone [orch, phsu]
CARDIOVASCULAR [bdsy]
Patients [podg]
Type 2 Diabetes [dsyn]
Artery [bpoc]
DIS [fndg]
